EP3631448A4 - Détection de par dans le lcr de patients atteints de la maladie de parkinson - Google Patents

Détection de par dans le lcr de patients atteints de la maladie de parkinson Download PDF

Info

Publication number
EP3631448A4
EP3631448A4 EP18810546.4A EP18810546A EP3631448A4 EP 3631448 A4 EP3631448 A4 EP 3631448A4 EP 18810546 A EP18810546 A EP 18810546A EP 3631448 A4 EP3631448 A4 EP 3631448A4
Authority
EP
European Patent Office
Prior art keywords
parkinson
csf
par
patients
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18810546.4A
Other languages
German (de)
English (en)
Other versions
EP3631448A1 (fr
Inventor
Ted Dawson
Valina DAWSON
Tae-In KAM
Liana ROSENTHAL
Shaida ANDRABI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority claimed from PCT/US2018/035614 external-priority patent/WO2018223003A1/fr
Publication of EP3631448A1 publication Critical patent/EP3631448A1/fr
Publication of EP3631448A4 publication Critical patent/EP3631448A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18810546.4A 2017-06-02 2018-06-01 Détection de par dans le lcr de patients atteints de la maladie de parkinson Withdrawn EP3631448A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514316P 2017-06-02 2017-06-02
PCT/US2018/035614 WO2018223003A1 (fr) 2017-06-02 2018-06-01 Détection de par dans le lcr de patients atteints de la maladie de parkinson

Publications (2)

Publication Number Publication Date
EP3631448A1 EP3631448A1 (fr) 2020-04-08
EP3631448A4 true EP3631448A4 (fr) 2021-03-03

Family

ID=69669605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810546.4A Withdrawn EP3631448A4 (fr) 2017-06-02 2018-06-01 Détection de par dans le lcr de patients atteints de la maladie de parkinson

Country Status (2)

Country Link
EP (1) EP3631448A4 (fr)
CN (1) CN110998321A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113533725A (zh) * 2021-06-23 2021-10-22 上海市肺科医院 一种肺动脉高压的发病风险和预后标记物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
WO2009152607A1 (fr) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Procédés et kits pour diagnostiquer une maladie neurodégénérative
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101661032A (zh) * 2008-08-29 2010-03-03 生物远景技术有限公司 帕金森病的生物标志物
US20170000836A1 (en) * 2013-05-22 2017-01-05 Sirbal Ltd. Prognostic and Diagnostic Methods and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
WO2009152607A1 (fr) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Procédés et kits pour diagnostiquer une maladie neurodégénérative
US20130022982A1 (en) * 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018223003A1 *

Also Published As

Publication number Publication date
EP3631448A1 (fr) 2020-04-08
CN110998321A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
EP3268086A4 (fr) Lsd pour le traitement de la maladie d'alzheimer
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
IL263188B (en) Treatment for Parkinson's disease
EP3721890A4 (fr) Préparation médicamenteuse ophtalmique et ses utilisations
GB201912244D0 (en) Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
EP3752840A4 (fr) Méthodes associées à la maladie de parkinson et aux synucléinopathies
EP3555319C0 (fr) Diagnostic de la maladie de parkinson sur la base d'une traduction globale réduite
EP3261446A4 (fr) Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson
EP3710010A4 (fr) Utilisation de hm4di dans le traitement de troubles épileptiques
EP3534918A4 (fr) Exosomes et leurs utilisations dans des maladies du cerveau
EP3631448A4 (fr) Détection de par dans le lcr de patients atteints de la maladie de parkinson
EP3713561A4 (fr) Combinaisons pharmaceutiques et méthodes pour le traitement du diabète et de troubles associés
EP3109636A4 (fr) Biomarqueur de la maladie de parkinson et son utilisation
EP3565636C0 (fr) Utilisation du microbiote intestinal dans le diagnostic de la maladie de parkinson
EP3606602A4 (fr) Stimulation cérébrale profonde dans la maladie de parkinson à un stade précoce
EP3162377A4 (fr) Utilisation d'alpha-asarone dans la préparation de médicaments pour prévenir et traiter la maladie d'alzheimer
EP3458058A4 (fr) Composition pharmaceutique et son utilisation dans le traitement de maladies auto-immunes
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
EP3244892A4 (fr) Procédés de traitement des troubles moteurs et du mouvement et effets secondaires de ceux-ci associés à des traitements de la maladie de parkinson
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
EP3549929A4 (fr) Dérivés silylés de resvératrol et leur utilisation dans des maladies neurrodégénératives, neurologiques ou inflammatoires
EP3359169A4 (fr) Diagnostic et traitement de la maladie de parkinson basés sur l'identification et l'amélioration d'un dysfonctionnement hépatique
EP3455366A4 (fr) Analyse de viscoélasticité chez des patients présentant une maladie associée au système cardiovasculaire
EP3474840A4 (fr) Utilisation de cyanoglucosides et leurs formulations pharmaceutiques dans le traitement du diabète

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210129

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20210125BHEP

Ipc: G01N 33/00 20060101ALI20210125BHEP

Ipc: G01N 33/53 20060101AFI20210125BHEP

Ipc: C12P 21/08 20060101ALI20210125BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20221020